Get the Stockscreener App
53.27
1.77%
-0.895
Biomarin Pharmaceutical Inc stock is traded at $53.27, with a volume of 189.98K.
It is down -1.77% in the last 24 hours and down -0.17% over the past month.
BioMarin is a global biotechnology company focused on developing and commercializing therapies for rare genetic diseases. BioMarin specializes in enzyme replacement therapies, gene therapies, and other advanced treatments designed to address complex genetic disorders. The company has eight approved therapies for conditions including achondroplasia, phenylketonuria, hemophilia, and mucopolysaccharidosis. BioMarin has an expanding, yet relatively early-stage, pipeline of treatments in development across skeletal conditions and enzyme therapies.
See More
Previous Close:
$54.16
Open:
$53.88
24h Volume:
189.98K
Relative Volume:
0.09
Market Cap:
$3.93B
Revenue:
$2.95B
Net Income/Loss:
$523.88M
P/E Ratio:
19.80
EPS:
2.69
Net Cash Flow:
$620.18M
1W Performance:
-3.83%
1M Performance:
-0.17%
6M Performance:
-10.45%
1Y Performance:
-14.15%
1-Day Range:
$52.90
$53.88
1-Week Range:
$52.90
$55.34
52-Week Range:
$50.76
$73.51
Biomarin Pharmaceutical Inc Stock (BMRN) Company Profile
Name
Biomarin Pharmaceutical Inc
Sector
Industry
Phone
(415) 506-6700
Address
105 DIGITAL DRIVE, NOVATO, CA
Compare BMRN with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BMRN
Biomarin Pharmaceutical Inc
|
53.25 | 10.40B | 2.95B | 523.88M | 620.18M | 2.69 |
|
ARGX
Argen X Se Adr
|
925.25 | 56.55B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
204.54 | 43.00B | 447.02M | -1.18B | -906.14M | -6.1812 |
|
VRTX
Vertex Pharmaceuticals Inc
|
429.82 | 110.50B | 11.74B | 3.68B | 3.34B | 14.19 |
|
ONC
Beone Medicines Ltd Adr
|
352.44 | 40.27B | 4.98B | 69.59M | 525.67M | 0.5197 |
|
REGN
Regeneron Pharmaceuticals Inc
|
716.27 | 76.23B | 14.25B | 4.58B | 3.88B | 41.77 |
Biomarin Pharmaceutical Inc Stock (BMRN) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-25 | Downgrade | Stifel | Buy → Hold |
| Sep-08-25 | Initiated | H.C. Wainwright | Neutral |
| Sep-03-25 | Initiated | Raymond James | Outperform |
| Jul-03-25 | Resumed | Morgan Stanley | Overweight |
| Feb-24-25 | Upgrade | Oppenheimer | Perform → Outperform |
| Nov-15-24 | Initiated | Wolfe Research | Outperform |
| Oct-30-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Aug-20-24 | Upgrade | Bernstein | Mkt Perform → Outperform |
| May-17-24 | Downgrade | Robert W. Baird | Outperform → Neutral |
| May-14-24 | Initiated | Evercore ISI | Outperform |
| Nov-15-23 | Initiated | Wells Fargo | Overweight |
| Oct-23-23 | Upgrade | Bernstein | Underperform → Mkt Perform |
| Sep-28-23 | Initiated | Raymond James | Mkt Perform |
| Sep-18-23 | Initiated | UBS | Buy |
| Jul-27-23 | Initiated | Scotiabank | Sector Perform |
| Jul-05-23 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Jun-14-23 | Resumed | Credit Suisse | Outperform |
| Mar-21-23 | Initiated | Bernstein | Underperform |
| Feb-22-23 | Downgrade | Oppenheimer | Outperform → Perform |
| Feb-21-23 | Initiated | Citigroup | Neutral |
| Jan-30-23 | Initiated | BMO Capital Markets | Market Perform |
| Jan-18-23 | Initiated | Canaccord Genuity | Hold |
| Oct-31-22 | Upgrade | Oppenheimer | Perform → Outperform |
| Jul-13-22 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-13-22 | Resumed | Wedbush | Neutral |
| Apr-25-22 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Nov-22-21 | Upgrade | William Blair | Mkt Perform → Outperform |
| Oct-07-21 | Resumed | Jefferies | Buy |
| Sep-09-21 | Upgrade | Stifel | Hold → Buy |
| Jun-04-21 | Resumed | Robert W. Baird | Outperform |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Mar-04-21 | Resumed | Guggenheim | Buy |
| Mar-01-21 | Upgrade | Evercore ISI | In-line → Outperform |
| Aug-20-20 | Downgrade | Citigroup | Buy → Neutral |
| Aug-20-20 | Downgrade | William Blair | Outperform → Mkt Perform |
| Aug-19-20 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-19-20 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Aug-19-20 | Downgrade | Stifel | Buy → Hold |
| Jul-08-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Jul-06-20 | Reiterated | Citigroup | Buy |
| Jan-28-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-27-20 | Initiated | BMO Capital Markets | Market Perform |
| Jan-24-20 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-27-19 | Upgrade | Barclays | Equal Weight → Overweight |
| Nov-12-19 | Initiated | SunTrust | Buy |
| Oct-17-19 | Resumed | BofA/Merrill | Buy |
| May-23-19 | Resumed | Citigroup | Buy |
| Apr-09-19 | Resumed | Raymond James | Outperform |
| Jan-02-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Dec-14-18 | Initiated | Wolfe Research | Outperform |
| Oct-01-18 | Initiated | Cantor Fitzgerald | Overweight |
| Aug-07-18 | Reiterated | Stifel | Buy |
| Aug-03-18 | Reiterated | Stifel | Buy |
View All
Biomarin Pharmaceutical Inc Stock (BMRN) Latest News
How BioMarin Pharmaceutical Inc. (BM8) stock responds to bond marketRate Cut & AI Optimized Trading Strategy Guides - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock attract long term capital inflowsJuly 2025 PostEarnings & Real-Time Volume Analysis - newser.com
How higher bond yields impact BioMarin Pharmaceutical Inc. (BM8) stockSell Signal & High Win Rate Trade Tips - newser.com
Is BioMarin Pharmaceutical Inc. (BM8) stock cheap vs fundamentalsMarket Performance Report & AI Forecast for Swing Trade Picks - newser.com
Will BioMarin Pharmaceutical Inc. stock split attract more investorsJuly 2025 Chart Watch & Momentum Based Trading Ideas - newser.com
What momentum indicators show for BioMarin Pharmaceutical Inc. stockMarket Trend Summary & Stepwise Swing Trade Plans - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock outperform global peersJuly 2025 Macro Moves & Real-Time Volume Triggers - newser.com
Will BioMarin Pharmaceutical Inc. (BM8) stock beat revenue estimatesMarket Volume Summary & Free Technical Pattern Based Buy Signals - newser.com
How currency fluctuations impact BioMarin Pharmaceutical Inc. stockJuly 2025 EndofMonth & Real-Time Sentiment Analysis - newser.com
Is BioMarin Pharmaceutical Inc. (BM8) stock undervalued historicallyTrade Volume Summary & Risk Controlled Stock Pick Alerts - newser.com
BioMarin stock touches 52-week low at $60.77 amid challenges - MSN
Biomarin at Jefferies Conference: Strategic Focus on Growth and Innovation By Investing.com - Investing.com Canada
Biomarin at Jefferies Conference: Strategic Focus on Growth and Innovation - Investing.com India
BMRN: Strategic execution and pipeline advances position for sustained growth in rare genetic diseases - TradingView
BMRN: Growth strategy, pipeline milestones, and global reach drive future opportunities and resilience - TradingView
How to monitor BioMarin Pharmaceutical Inc. with trend dashboardsJuly 2025 News Drivers & AI Powered Market Entry Ideas - newser.com
Using AI based signals to follow BioMarin Pharmaceutical Inc.Weekly Earnings Recap & High Win Rate Trade Alerts - newser.com
Exit strategy if you’re trapped in BioMarin Pharmaceutical Inc.Dividend Hike & Consistent Income Trade Ideas - newser.com
Can BioMarin Pharmaceutical Inc. (BM8) stock reach $200 price targetMarket Trend Review & Fast Exit Strategy with Risk Control - newser.com
Key resistance and support levels for BioMarin Pharmaceutical Inc.2025 Dividend Review & Real-Time Volume Analysis Alerts - newser.com
How strong is BioMarin Pharmaceutical Inc. stock balance sheetPortfolio Return Summary & Verified Swing Trading Watchlists - newser.com
(BMRN) Volatility Zones as Tactical Triggers - news.stocktradersdaily.com
Biomarin Pharmaceutical Inc Stock (BMRN) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
2.05%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):